Catalogo dei prodotti della ricerca

PANZUTO, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.323
EU - Europa 1.558
AS - Asia 613
AF - Africa 34
SA - Sud America 24
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.557
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.262
IT - Italia 771
SG - Singapore 306
SE - Svezia 199
IN - India 174
IE - Irlanda 146
UA - Ucraina 127
FI - Finlandia 118
CN - Cina 106
BE - Belgio 50
CA - Canada 50
DE - Germania 37
GB - Regno Unito 37
BG - Bulgaria 18
AR - Argentina 16
TG - Togo 15
RO - Romania 11
CH - Svizzera 9
HK - Hong Kong 9
FR - Francia 8
MX - Messico 7
NG - Nigeria 7
BR - Brasile 6
PT - Portogallo 6
AT - Austria 5
UG - Uganda 5
DZ - Algeria 4
SI - Slovenia 4
AU - Australia 3
ES - Italia 3
JP - Giappone 3
NL - Olanda 3
PH - Filippine 3
PK - Pakistan 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
KR - Corea 2
RS - Serbia 2
SA - Arabia Saudita 2
TW - Taiwan 2
BY - Bielorussia 1
CL - Cile 1
EU - Europa 1
IQ - Iraq 1
IR - Iran 1
IS - Islanda 1
LI - Liechtenstein 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PL - Polonia 1
VE - Venezuela 1
Totale 6.557
Salva come PNG Salva come JPEG
Città #
Fairfield 836
Chandler 318
Ashburn 307
Houston 282
Woodbridge 278
Seattle 261
Rome 228
Singapore 213
Cambridge 204
Wilmington 191
Dublin 144
Princeton 123
Ann Arbor 107
Lawrence 100
San Paolo di Civitate 93
San Diego 82
Millbury 72
Plano 63
Milan 61
Beijing 56
New York 56
Boston 53
Brussels 50
Jacksonville 46
Santa Clara 41
Helsinki 37
Dearborn 33
Ottawa 29
Norwalk 23
Lappeenranta 22
Andover 21
Shanghai 20
Boardman 18
Sofia 18
Des Moines 17
Federal 16
Toronto 16
Lomé 15
Bari 14
Bologna 14
Genoa 11
London 11
Falls Church 8
Fara in Sabina 8
Nanjing 8
Naples 8
Padova 8
San Mateo 8
Stockholm 8
Bühl 7
Dallas 7
Florence 7
Fremont 7
Lagos 7
Verona 7
Calvanico 5
Grottammare 5
Hong Kong 5
Kampala 5
Mexico City 5
Perugia 5
Phoenix 5
Pontedera 5
Turin 5
Villaricca 5
Catania 4
Falkenstein 4
Guangzhou 4
Ljubljana 4
Los Angeles 4
Mannheim 4
Paris 4
Redmond 4
San Benedetto del Tronto 4
Tenhult 4
Terni 4
Venice 4
Alba 3
Benevento 3
Bisceglie 3
Bremen 3
Cebu City 3
Como 3
Deruta 3
Hebei 3
Hefei 3
Hyderabad 3
Islamabad 3
Kunming 3
Lisbon 3
Livorno 3
Palmetto 3
Pune 3
Recanati 3
Santa Croce sull'Arno 3
Segrate 3
Spilamberto 3
Springfield 3
Valsayn 3
Veroli 3
Totale 4.865
Salva come PNG Salva come JPEG
Nome #
Il valore aggiunto della RLT. che cosa insegna l’esperienza clinica nei tumori neuroendocrini 115
A case of pancreatic small cell neuroendocrine carcinoma associated with SIADH 109
Endocrine tumours of the stomach 107
Nasogastric or nasointestinal feeding in severe acute pancreatitis 101
Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. 98
European Neuroendocrine Tumor Society (ENETS) 2023 Guidance Paper for Gastroduodenal NET G1‐G3 97
CT texture analysis of liver metastases in PNETs versus NPNETs. correlation with histopathological findings 96
Abdominal tuberculosis with pancreatic involvement: a case report 91
[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia 88
Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms 87
Functional imaging in the follow-up of enteropancreatic neuroendocrine tumors. Clinical usefulness and indications 86
Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas 86
Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis 85
Role of combined [68Ga]Ga-DOTA-SST analogues and [18F]FDG PET/CT in the management of GEP-NENs. a systematic review 84
Gastric neuroendocrine tumors. 82
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence 81
Real-world study of everolimus in advanced progressive neuroendocrine tumors. 80
Oesophageal GIST. MDCT findings of two cases and review of the literature 80
[18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia 79
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization 78
Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections 76
Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours 74
Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors 74
Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors 74
Corpus-predominant gastritis as a risk factor for false-negative 13C-urea breath test results. 73
Acute fulminant hepatitis E virus genotype 3e infection: Description of the first case in Europe. 73
Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. 72
Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs 71
Co-existence of hyperparathyroidism, hypergastrinaemia and multiple gastric carcinoids is not always due to incomplete expression of the MEN-1 syndrome 70
Intragastric ascorbic but not uric acid is depleted in relation with the increased pH in patients with atrophic body gastritis and H. pylori gastritis. 70
Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy. 69
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 69
Heterogeneity of duodenal neuroendocrine tumors: an Italian multi-center experience 67
Rhabdomyolysis due to severe hypokaliemia in a Crohn's disease patient after budesonide treatment 66
Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. 66
Radiopharmaceuticals for breast cancer and neuroendocrine tumor. Two examples of how tissue characterization may influence the choice of therapy 66
Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors 65
Digestive neuroendocrine neoplasms. A 2016 overview 65
Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives 64
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study 64
Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours 64
Theranostic designed near-Infrared fluorescent poly (lactic-co-glycolic acid) nanoparticles and preliminary studies with functionalized VEGF-nanoparticles 64
Molecular pathology and genetics of pancreatic endocrine tumours 63
Evaluation of the relationships between computed tomography features, pathological findings, and rrognostic risk assessment in gastrointestinal stromal tumors 63
Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center 63
Clinical and pathological features of synchronous gastrointestinal stromal tumors presenting associated with other malignancies 62
Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia. A Case Series 61
Phenotype Expression in a Case of Adult Cystic Fibrosis Caused by an Extremely Rare Compound Heterozygous Genotype (2183AA > G/2789+5G > A) 59
Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment 59
Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). 59
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 59
SARS-CoV2 RNA detection in a pancreatic pseudocyst sample 59
Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells 58
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 58
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma 58
Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients 57
Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy 56
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs. A Multicenter Study 56
Unlabelled somatostatin analogues in treatment of digestive endocrine tumours 55
Iron deficiency anemia caused by nonspecific (idiopathic) small bowel ulceration. an uncommon presentation of an uncommon disease 54
Long-term octreotide treatment of metastatic carcinoid tumor 54
Peanut-like 1 (septin 5) gene expression in normal and neoplastic human endocrine pancreas 54
Late recurrence after surgical resection of a pancreatic tumor in von Hippel-Lindau disease 53
Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia. A systematic review 52
Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia. A Systematic Review 51
Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition. A prospective study 51
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. 48
Somatostatin receptor subtypes: basic pharmacology and tissue distribution 47
Advanced digestive neuroendocrine tumors. metastatic pattern is an independent factor affecting clinical outcome 47
Medical treatment of digestive neuroendocrine tumours 46
Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. 46
Management of type-I gastric neuroendocrine neoplasms. A 10-years prospective single centre study 46
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 46
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia. a multicentre retrospective study 45
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia 44
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm. Study Protocol for a Prospective Observational Study 43
Clinical challenges in the management of neuroendocrine tumors 43
ANALOGHI DELLA SOMATOSTATINA: PROSPETTIVE FUTURE 41
Nonconventional doses of somatostatin analogs in patients with progressing well-differentiated neuroendocrine tumor 41
Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms 41
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms. The NOVARA Score, a Multicentre Retrospective Study 40
A case report of multiple gastrointestinal stromal tumors: imaging findings, surgical approach, and review of the literature 40
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. A Multicentric Retrospective Study 39
Prognostic significance of laterality in lung neuroendocrine tumors 39
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors 38
Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms. Data from a large international cohort study 38
The meaning of R1 resection after endoscopic removal of gastric, duodenal and rectal neuroendocrine tumors 37
Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function 36
The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs 36
“TC nelle lesioni secondarie epatiche da tumore neuroendocrino del tratto gastroenteropancreatico: protocollo con doppia fase arteriosa” 35
Efficacy of lutetium-peptide receptor radionuclide therapy in inducing prolonged tumour regression in small-bowel veuroendocrine tumours. A case of favourable response to retreatment after Initial objective response 35
Linee guida NEOPLASIE NEUROENDOCRINE 34
Bone Metastases in Neuroendocrine Tumors. Molecular Pathogenesis and Implications in Clinical Practice 34
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 33
Nuclear medicine and radiological imaging of pancreatic neuroendocrine neoplasms: a multidisciplinary update 33
[Chemotherapy and NSAIDs in neoplastic disease. Role of anti-secretory preventive therapy]. 33
Large Cell Neuroendocrine Carcinoma of the Lung. Current Understanding and Challenges 33
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors. rationale and protocol of the phase II LOLA trial 32
Therapy of NET with radiolabeled SST analogs 32
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 31
Totale 6.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.858
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.858
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020931 0 0 20 46 109 135 153 138 135 97 55 43
2020/2021470 64 52 38 43 12 29 6 43 47 59 43 34
2021/20221.768 5 55 82 30 124 29 39 120 406 189 466 223
2022/20231.459 265 300 82 141 135 102 18 63 227 33 60 33
2023/20241.088 57 101 61 111 82 140 99 87 18 107 128 97
2024/2025477 119 117 241 0 0 0 0 0 0 0 0 0
Totale 7.115